Skip to main navigation menu Skip to main content Skip to site footer
Brazilian Journal of Clinical Medicine and Review

Health Review

Vol. 4 No. 1 (2026): January/December - 2026

Viscoelastic-Guided Hemostatic Resuscitation in Trauma: From Endothelial Endotype to System-Level Precision

DOI
https://doi.org/10.52600/2965-0968.bjcmr.2026.4.1.bjcmr60
Submitted
February 10, 2026
Published
2026-03-07

Abstract

Trauma-induced coagulopathy (TIC) is a biologically heterogeneous and rapidly evolving response to severe injury characterized by endothelial dysfunction, dysregulated thrombin generation, platelet impairment, and divergent fibrinolytic phenotypes. While balanced transfusion strategies have improved early hemorrhage control, they do not fully account for the phenotypic variability observed in TIC. Viscoelastic hemostatic assays (VHA), including thromboelastography and rotational thromboelastometry, provide real-time assessment of clot formation, strength, and fibrinolysis, enabling targeted hemostatic resuscitation. However, randomized trials have demonstrated improvements in transfusion targeting without consistent reductions in overall mortality. This structured narrative review synthesizes contemporary evidence on the biological mechanisms of TIC, fibrinolytic endotypes, and the role of viscoelastic testing in trauma resuscitation. A systematic search of PubMed/MEDLINE, Scopus, and Web of Science from January 2000 to February 2026 was performed, prioritizing landmark randomized trials, mechanistic studies, and international guidelines. The literature suggests that the effectiveness of VHA-guided resuscitation is influenced not only by diagnostic capability but also by the interaction between biological phenotype, timing of intervention, and trauma system performance. A hybrid model integrating early empiric balanced transfusion with subsequent phenotype-guided calibration may represent the most physiologically coherent strategy. Ultimately, viscoelastic testing should be understood as a decision-support modality embedded within mature trauma systems rather than a standalone determinant of survival. Future research should focus on phenotype-stratified clinical trials and system-integrated approaches capable of translating hemostatic precision into consistent outcome improvement.

References

  1. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54(6):1127–1130.
  2. Brohi K, Cohen MJ, Davenport RA. Acute traumatic coagulopathy: initiated by hypoperfusion. Ann Surg. 2007;245(5):812–818.
  3. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy. Nat Rev Dis Primers. 2021;7:30.
  4. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–482.
  5. Baksaas-Aasen K, Gall LS, Stensballe J, et al. Trauma hemorrhage resuscitation with viscoelastic assay-guided therapy: the ITACTIC randomized controlled trial. Intensive Care Med. 2021;47(2):186–198.
  6. Cannon JW. Hemorrhagic shock. N Engl J Med. 2018;378(4):370–379.
  7. Simmons JW, Pittet JF, Pierce B. Acute traumatic coagulopathy: pathophysiology and resuscitation. Br J Anaesth. 2016;117(Suppl 3):iii31–iii43.
  8. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy. Nat Rev Dis Primers. 2021;7:30.
  9. Moore HB, Moore EE, Liras IN, et al. Fibrinolysis shutdown in trauma. J Am Coll Surg. 2017;224(6):1091–1101.
  10. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated Eu-ropean guideline. Crit Care. 2019;23:98.
  11. Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. 2023;27:81.
  12. CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32.
  13. CRASH-3 Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713–1723.

Most read articles by the same author(s)